Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 38
The Years Ahead in Biomedical HIV Prevention Research
This graphic shows the updated status of large-scale prevention trials through the end of 2024.
HIV Vaccine and Antibody Efficacy Trials to Date
This infographic provides a comprehensive overview of HIV vaccine and antibody efficacy trials. Over 20 years and 12 trials, only two positive signals have been observed.
Prevention Option:
The HIV Prevention Pipeline
This graphic shows currently available options for HIV prevention, newly approved and recommended treatment, and those in development.
Prevention Option:
Px Wire September 2023
PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of PxWire.
HIV-Specific Neutralizing Antibodies by Target
A number of broadly neutralizing antibodies that target various regions of HIV’s Env protein are being developed for HIV prevention.
Prevention Option:
Biomedical HIV Prevention Research in 2022 and Beyond
This report provides a concise update on the full landscape of biomedical interventions: including PrEP products in the market and next-gen products in the pipeline—multipurpose products (MPTs), vaccines and broadly neutralizing antibodies.
Prevention Option:
Experimental Medicine Vaccine Trials (EMVTs): Opportunities and Challenges
A look at an innovative trial design to safely speed the discovery of viable vaccine candidates. The focus of EMVTs is to accelerate vaccine science rather than progress individual products.
Prevention Option:
Understanding Results of the AMP Trials
The AMP trials evaluated the ability of a broadly neutralizing antibody (bNAb), called VRC01, to protect against HIV.
Prevention Option:
Dive into the AMP Trials
In this episode of Px Pulse, AVACers Jeanne Baron and Daisy Ouya talk to leading bNAb researcher, IAVI’s Devin Sok; a veteran HIV research advocate Mark Hubbard who served on AMP’s protocol team; and a senior member of the HVTN’s community engagement team, a chief explainer of the AMP trails, Gail Broder.
Prevention Option:
Broadly Neutralizing Antibody Combinations
Overview of the combinations of broadly neutralizing antibodies (bNAbs) under investigation in early clinical studies for HIV prevention.
Prevention Option:
showing 1-10 of 38